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1. Introduction
A tremendous effort has been and is currently being devoted to the research in the field of
pharmaceutical nanotechnology. Several peculiar properties of gelled polymeric nanosize
(<1μm) particulate systems have been reported, among which the ability to encapsulate either
small molecular weight or macromolecular active principles in mild conditions and protect
them from degradation by the harsh pH conditions or enzymes they may encounter in the
organism, promote transport of actives across mucosal barriers, undergo internalization by
cells thereby carrying actives into them. Chitosan, a copolymer of glucosamine and N-
acetylglucosamine, obtained by deacetylation of the naturally-occurring chitin, has been
studied as a basic biomaterial for preparing pharmaceutical nanoparticles, because it is
biodegradable and has a very low toxicity [1-5] besides an ability to promote transport of drugs,
peptides and proteins across mucosal barriers [6-10]. The preparation procedures of chitosan
nanoparticles, their characterization for drug encapsulation efficiency, physical and biophar‐
maceutical properties, and toxicity have been covered by recent reviews (11,12). Chitosan has
been subjected to derivatization, taking advantage of the reactivity of the primary amino group
in position 2, or the hydroxyl group in position 6 of its repeating unit, glucosamine. The
derivatization changed the physicochemical, biopharmaceutical and biological properties of
the parent chitosan and each derivative type lent itself to preparing nanoparticles with their
own physical properties (size, shape, surface charge), drug encapsulation and release capa‐
bility, biopharmaceutical and biological properties (mucoadhesivity, ability to promote drug
transport across biological barriers, aptitude for internalization within cells, citotoxicity).
In the following sections the nanoparticles obtained from chitosan derivatives will be surveyed
in respect to preparation procedures, interactions with cells and tissues, factors influencing
biological properties, pharmaceutical applications.
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2. Preparation procedures
2.1. Ionotropic gelation
Ionotropic gelation, that is by far the most used technique for preparation of nanoparticles
from chitosan derivatives, was first reported in 1997 by Calvo et al. [13]. The basic concept is
that a polycationic polymer in aqueous solution passes, in appropriate conditions, from sol to
dispersed gel following electrostatic crosslinking with an adequate anionic substance. This
technique has been used with several quaternized chitosans carrying fixed, pH-independent
positive charges, the most known of which is N-trimethyl chitosan (TMC). Sodium tripoly‐
phosphate (TPP) has widely been employed as the ionotropic crosslinker [14-19].
The nanoparticles prepared by ionotropic gelation of quaternized chitosans with TPP were
generally 200-300 nm in size, i.e., smaller than those obtained by the same method starting
from plain chitosan which, by the way, showed lesser stability and tended to re-dissolve after
some time from formation. The zeta potential was always positive, in the 10-20 mV range. The
solution of the chitosan derivative into which the TPP solution was dripped would often
contain a surfactant, usually Tween 80, to hinder nanoparticle aggregation and facilitate their
re-dispersion after centrifugation. In fact, centrifugation was necessary to clear the particles of
non-encapsulated drug.
The technique under discussion has also been used to prepare nanoparticles from thiolated
derivatives of chitosan [20-23].
These polymers have shown mucoadhesive properties due to the ability of their thiol groups
to form covalent disulfide bridges by reacting with the thiol residues present on the glyco‐
proteins of mucus. For this reason the nanoparticles derived from these chitosan derivatives
were themselves endowed with mucoadhesivity. The thiolated nanoparticles formed by
ionotropic gelation with TPP were stabilized via oxidation of thiols with H2O2 which formed
interchain disulfide bonds. These would bestow gastroresistance on the particles, which would
be particularly appropriate in case of oral administration of the nanoparticle formulation.
However the presence of some non-oxidized thiols on the nanoparticle surface was needed to
confer enhanced mucoadhesivity on such a surface. This goal was actually achieved by
Bernkop-Schnurch et al. [21]. These authors also studied the crosslinker effect on nanoparticle
size. Under similar preparation conditions, sizes in the 200-300 nm range were obtained with
TPP as the crosslinker, whereas sizes beyond the micron resulted using Na2SO4.
2.2. Gelation from polyelectrolyte complex (PEC) formation
This method involved ionotropic gelation, just as described in the preceding section, only in
the present case the crosslinker was a polyanionic polymer with charges opposite to those of
the chitosan derivative, with which it formed a PEC. To this purpose N-carboxymethyl
chitosan, poly(γ-glutamic acid), poly(aspartic acid) and hyaluronic acid were used as polyan‐
ions, while TMC and glycidyl trimethyl ammonium chitosan were the polycations [24-27]. In
a case both the polyanion (hyaluronic acid) and the polycation (TMC) were thiolated and the
nanoparticles were stabilized by the formation of interchain disulfide bonds [28].
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2.3. Polymer-drug complexes
Some negatively charged active principles, such as insulin or gene drugs, when mixed with
cationic chitosan derivatives in adequate proportions spontaneously formed nanoparticulate
dispersions of insoluble complexes [29-34]. TMC nanoparticles obtained by ionotropic gelation
with TPP in the presence of insulin were compared with nanoparticles obtained by PEC
formation between TMC and insulin. In the latter instance higher encapsulation efficiency and
zeta potential (positive), and smaller particle size were observed, which is particularly
appropriate for particle internalization into cells. In addition, a higher stability in simulated
intestinal fluid (pH 6.8) of the nanocomplex compared to the nanoparticles prepared with TPP
resulted [31,32].
2.4. Self-assembly
Amphiphilic derivatives of chitosan in aqueous solution were found, at a critical aggregation
concentration (CAC), to spontaneously arrange into nanoparticles of sizes in between 100-400
nm. Such derivatives were prepared by connecting hydrophobic structures to the chitosan or
glycol chitosan backbone via the amino group of the chitosan repeating unit. Examples of the
above amphiphilic derivatives are the following: glycol chitosan-5β-cholanic acid conjugate
[35-40]; palmitoyl chitosan [41]; palmitoyl glycol chitosan [42]; oleoyl chitosan [43]. Other
amphiphiles were prepared from chitosans bearing fixed positive charges, in the case of
quaternary ammonium palmitoyl glycol chitosan [42], or negative fixed charges, as in the case
of linoleic acid-modified O-carboxymethyl chitosan [44], or deoxycholic acid-modified N,O-
carboxymethyl chitosan [45]. Usually, after suspending the polymer in an aqueous medium,
probe sonication was applied to limit particle size. The formation of nanoparticles was
monitored and the CAC determined fluorometrically, or through UV absorption spectra, or
measuring the enthalpy change by a microcalorimeter [42,44,45].
The CAC for the hydrophobically modified chitosan derivatives is usually in the μM range,
whereas the CMC of small-molecular weight surfactants is in the mM range. This is one of the
most important characteristics of amphiphilic polymers, pointing to stability of the self-
aggregates in dilute conditions, such as those the nanoparticles are supposed to encounter after
administration to the organism. The CAC values of these polymers have been found to
decrease with increasing hydrophobic content of derivatives [44]. In fact, the nanoparticles
formed from these chitosan derivatives are characterized by a core-shell structure, i.e., a
hydrophobic core in a hydrophilic shell. The drug incapsulation method was chosen on the
basis of the hydrophilic or hydrophobic nature of the drug. With hydrophobic drugs the
solution of polymer and drug in a water-miscible organic solvent was mixed with an aqueous
medium and the organic solvent was cleared away by dialysis or evaporation [36,39,40].
Hydrophobic drugs having a fair water solubility and polar drugs have been loaded into
nanoparticles via direct addition to the aqueous polymer dispersion [41,42,44,45]. The non-
encapsulated drug has been separated by ultracentrifugation, filtration or dialysis.
Nanoparticles Based on Chitosan Derivatives
http://dx.doi.org/10.5772/54944
245
3. Interactions with cells and tissues
3.1. Quaternized derivatives
Chitosan has been found to open the tight junctions connecting epithelial cells, through an
interaction of its positively charged amino groups with negatively charged sites in the tight
junctions, thereby promoting paracellular transepithelial absorption of drugs, peptides and
proteins [10,46-57]. The major drawback of unmodified chitosan as an absorption promoter is
its insolubility at physiological neutral pH. Therefore the primary amino groups of its
repeating units have been quaternized to bestow fixed, pH-independent positive charges on
the polymer, thus making it soluble and active as an absorption promoter at physiological pH.
In fact, TMC was found to act as an enhancer of drug, peptide and protein permeability across
intestinal, nasal, buccal, ocular epithelium [47, 58-66]. TMC was shown to promote not only
paracellular but also transcellular drug absorption [66]. Other quaternized chitosan deriva‐
tives, namely, N-triethylchitosan (TEC) [68], N,N-dimethyl N-ethylchitosan (DMEC) [69] and
N,N-diethyl N-methylchitosan (DEMC) [70] have been synthesized. Positively charged
chitosan and its quaternized derivatives have also exhibited mucoadhesive properties,
determined by ionic interactions with the negatively charged sialic acid residues of mucins at
neutral or slightly alkaline pH [71].
Particles in the nanosize range have resulted from the interaction of quaternized chitosans with
polyanions. Proteins or macromolecular drug models have been encapsulated in these
nanoparticles. Ovalbumin (OVA) was encapsulated in nanoparticles, obtained by ionotropic
gelation of TMC with TPP, and studied as a nasal delivery system for proteins [19]. No
cytotoxicity of nanoparticles on Calu-3 cells, a model of human respiratory function, was
evidenced, whereas a partially reversible cilio-inhibiting effect on the ciliary beat frequency of
chiken trachea was observed. Confocal laser scanning microscopy (CLSM) of nasal epithelia
and nasal associated lymphoid tissue (NALT), incubated with nanoparticles loaded with
fluorescein-labelled albumin, showed the presence of fluorescent nanoparticles throughout
the cytoplasm of these cells, indicating the transport of albumin-associated TMC/TPP nano‐
particles across the nasal mucosa. These findings led the authors to point to these nanoparticles
as a potential delivery system for transport of proteins through the nasal mucosa
Other authors studied similar TMC/TPP nanoparticles, loaded with fluorescein isothiocyanate
dextran, molecular weight 4400 Da (FD4), as a model of macromolecular drugs [17]. In analogy
with the free TMC, the TMC/TPP nanoparticles exhibited the property of opening the tight
junctions between cells in the Caco-2 monolayer in vitro and the rat intestinal epithelium ex
vivo, thus promoting the permeation of FD4 across the two epithelium models. The nanopar‐
ticles also shared, with the free TMC, the property of adhering to the intestinal mucosa. Using
CLSM, Sandri et al. [17] showed internalization of their nanoparticles into Caco-2 cells and
excised rat jejunum tissue.
Nanoparticles encapsulating fluorescein-labelled bovine serum albumin (BSA) were obtained
by ionotropic gelation of alginate-modified TMC with TPP [16]. According to the authors the
transport of alginate-modified TMC nanoparticles across the Caco-2 cell in vitro model of
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gastrointestinal (GI) epithelium was more efficient than that produced by non-modified TMC
nanoparticles. However, alginate modification barely had any effect on the trans-epithelial
electrical resistance or on paracellular protein transport. Then the hypothesis was made that
alginate modification facilitated nanoparticle transport across the Caco-2 monolayer by the
transcellular route (transcytosis) by virtue of a reduction of particle size to 100-200 nm (16).
The supposedly permeated nanoparticles were assayed by measuring the fluorescence of
fluorescein-labelled BSA, which was assumed to be completely associated with the particles.
Similar nanoparticles as the above were loaded with urease, a vaccine protein against
Helicobacter pylori infection. Immunization studies in mice showed that oral administration of
urease-loaded TMC nanoparticles generated high titers of both IgG and S-IgA antibodies. The
immunostimulating effect was caused by nanoparticle mucoadhesivity and transcytosis by M
cells in gut associated lymphoid tissue [16].
OVA-loaded nanoparticles have been prepared from TMC using unmethylated CpG DNA as
adjuvant and crosslinker, in place of TPP, for nasal vaccination in mice [15]. TMC/CpG/OVA
showed similar physical properties as TMC/TPP/OVA in terms of particle size, zeta-potential
and antigen release characteristics, but TMC/CpG/OVA induced a 10-fold higher IgG2a
response than TMC/TPP/OVA, and a strong humoral and Th1 type cellular immune responses
after nasal vaccination [15].
Nanoparticles derived from the polyelectrolytic complexation of TMC by the polyanionic
mono-N-carboxymethyl chitosan (MCC), and loaded with fluorescein-labelled BSA were
taken up into mouse Balb/c monocyte macrophages. Mice were nasally immunized with
tetanus toxoid-loaded TMC/MCC complex nanoparticles. These were shown to induce both
mucosal and systemic immune response [24].
Insulin was formulated into nanoparticles formed from quaternized chitosans such as TMC
or DEMC via either ionotropic gelation with TPP, or polyelectrolyte complexation by the
polyanionic insulin. The PEC method resulted in higher insulin loading efficiency and
nanoparticle zeta-potential [31].
Similar nanoparticulate systems loaded with insulin were prepared from other quaternized
chitosans, namely, N-triethyl chitosan (TEC) and N-dimethylethyl chitosan (DMEC), by the
PEC method [30]. Insulin was transported ex vivo across the colon membrane of rats when it
was formulated into nanoparticles made of quaternized derivatives, better than into those
made of plain chitosan. In vivo colon absorption of insulin was enhanced by using insulin-
loaded nanoparticles compared to free insulin. Insulin absorption from rat colon was evaluated
by its hypoglycemic effect [30].
Poly(γ-glutamic acid) was used by Mi et al. [25] as the anionic polyelectrolyte complexing
agent to prepare nanoparticles from TMC by the PEC method, for the oral delivery of insulin.
According to the authors insulin was transported across the Caco-2 cell in vitro model of GI
epithelium via the paracellular route. In fact, CLSM confirmed the opening of the tight
junctions between cells caused by the nanoparticles. The authors propose a mechanism
whereby the orally administered nanoparticles with mucoadhesive TMC on their surfaces may
adhere and infiltrate into the intestinal mucus, mediate the opening of tight junctions between
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enterocytes, undergo disintegration, and release insulin, which would permeate through the
paracellular pathway to the bloodstream. This hypothesis is contrasting with that, proposed
by Chen et al. [16], of protein being carried by TMC/alginate/TPP nanoparticles across the
Caco-2 monolayer by transcytosis.
TMC was modified with the specific ligand CSKSSDYQC peptide (CSK) to prepare ionotrop‐
ically crosslinked TMC-CSK/TPP nanoparticles, loaded with fluorescein isothiocyanate
(FITC)-labelled insulin, targeted to the mucus-producing goblet cells [45]. In transport studies
across Caco-2/HT29-MTX co-cultured cell monolayer, simulating mucus-producing intestinal
epithelium, the CSK modification showed enhanced drug transport ability, even if the target
recognition was partially affected by mucus. In pharmacological and pharmacokinetic studies
in diabetic rats, the orally administered CSK-modified nanoparticles produced a stronger
hypoglycemic effect than the unmodified ones, prompting the authors to state that the former
were sufficiently effective as goblet cell-targeting nanocarriers for oral delivery of insulin.
An oral delivery system for paclitaxel, a mitotic inhibitor used in cancer chemotherapy, was
devised by encapsulating the drug in N-(2-hydroxy-3-trimethylammonium) propyl chitosan
chloride (HTCC) nanoparticles prepared by the O/W/O double emulsion temperature-
programmed solidification method [72]. CLSM studies suggested that the HTCC nanoparticles
could be transported across Caco-2 monolayers via the opening of tight junctions between
cells. Also the in vivo absorption of these nanoparticles by the small intestine of rats was shown.
These transport properties of nanoparticles were ascribed to their positive surface charge,
which was also considered responsible for an enhanced nanoparticle uptake by carcinoma
cells. Biodistribution studies after oral administration in subcutaneous LLC tumor-bearing
mice showed accumulation of paclitaxel-loaded HTCC nanoparticles in liver, spleen, lung, and
kidney tissues, which was ascribed to the uptake of nanoparticles by the reticuloendothelial
system, and in tumour tissue through the enhanced permeability and retention (EPR) effect.
These results are particularly intriguing as they open the prospect of a targeted oral treatment
of cancer by nanomedicine.
3.2. Thiolated derivatives
The thiol groups immobilized on these polymers are supposed to give exchange reactions with
disulfide bonds within the mucus, or oxidation reactions with cysteine-rich subdomains of
mucus glycoproteins [73, 74], both resulting in the formation of disulfide bonds between
thiolated chitosan derivatives and the mucus, which improve the polymer mucoadhesivity.
Nanoparticles prepared from this type of chitosan derivatives were supposed to be themselves
mucoadhesive, and hence, apt to make nanocarriers for oral drug delivery. In fact, enhanced
mucoadhesive properties of nanoparticles prepared by gelation of chitosan-N-acetyl cysteine
conjugate (chitosan-NAC) with TPP, compared with unmodified chitosan nanoparticles, were
found by Wang et al. [23]. Enhanced insulin in vivo absorption via nasal mucosa was found
by these authors when insulin-loaded chitosan-NAC/TPP nanoparticles were administered
intranasally to rats.
Another thiolated chitosan derivative, chitosan-4-thiobutylamidine (chitosan-TBA) was used
by Bernkop-Schnürch et al. [22] to develop a mucoadhesive nanoparticulate delivery system.
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The polymer was first crosslinked ionotropically by TPP, followed by stabilization of the
resulting nanoparticles via formation of inter- and intrachain disulfide bonds by thiol oxidation
with H2O2. Subsequently, TPP was removed by dialysis. The covalently crosslinked particles
would not disintegrate in the acidic medium of the stomach. The adhesion to porcine intestinal
mucosa was studied after incorporation of fluorescein diacetate into nanoparticles. The more
thiol groups were oxidized, the lower was the nanoparticle mucoadhesivity, nevertheless, even
when as much as 90% of all thiols were oxidized the mucoadhesivity of chitosan-TBA nano‐
particles was twice as high as that of unmodified chitosan nanoparticles.
Polymer Gelling agent Drug Diameter (nm) Zeta potential(mV) Reference
TMC-CSK TPP insulin 200-350 3-10 [14]
HTCC
o/w/o double
emulsion paclitaxel 130 21 [72]
TMC cisplatin-hyaluronate cisplatin 450 45 [27]
TMC TPP OVA 300 20 [15]
TMC MCC tetanus toxoid,FITC-BSA not reported not reported [24]
HTCC poly(aspartic acid) BSA 200-300 55 [26]
TMC poly(γ-glutamicacid) insulin 100 30 [25]
TEC, DMEC insulin insulin 200 25 [30]
TMC, DEMC TPP, insulin insulin 250 25 [31]
TMC TPP FITC-BSA 300 14 [16]
TMC TPP OVA 254-300 20-61 [19]
TMC TPP FD4 200 - [17]
Table 1. Main characteristics of nanoparticles based on quaternized chitosans
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Polymer Gellingagent Drug
Diameter
(nm)
Zeta
potential
(mV)
Reference
chitosan-NAC
TPP insulin 140-210 19-31 [23]
chitosan-TGA
DNA DNA 75-120 2-20 [34]
chitosan-TBA
TPP none 268 4-19 [22]
chitosan-TBA TPP none 240 5-11 [21]
thiolated TMC thiolatedHA OVA 250-350 10-20 [28]
chitosan-TGA none pSEAP 212-113 4-8 [33]
glycol chitosan-TGA
TPP calcitonin 230-330 21-27 [20]
Table 2. Main characteristics of nanoparticles based on thiolated chitosan derivatives
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Glycol chitosan coupled with thioglycolic acid (TGA) was ionotropically gelled with TPP to
yield nanoparticles, which showed a twofold increase in mucoadhesion to lung tissue after
intra-tracheal administration to rats as compared to non-thiolated nanoparticles. Biocompat‐
ibility of nanoparticle formulations with lung tissue was demonstrated. Calcitonin-loaded
glycol chitosan and glycol chitosan-TGA nanoparticles resulted in a pronounced hypocalcemic
effect for at least 12 and 24 h and a bioavailability of 27 and 40%, respectively [20].
Verheul et al. [28] used the thiol groups of thiolated TMC to spontaneously form interchain
disulfide crosslinks with the thiols of thiolated hyaluronic acid (HA), after ionic gelation. OVA-
loaded stabilized TMC-S-S-HA nanoparticles demonstrated higher immunogenicity than not
stabilized particles, indicated by higher IgG titers, in nasal and intradermal vaccination.
Besides showing enhanced mucoadhesivity and cell penetration properties, nanoparticles
made of thiolated chitosans have appeared highly effective as gene delivery systems. Thiolated
derivatives, prepared from 33-kDa chitosan by coupling with TGA, formed nanocomplexes
with plasmid DNA encoding green fluorescent protein (GFP), that were able to bind and
protect plasmid DNA from Dnase I digestion. Thiolated chitosan/DNA nanocomplexes
induced higher GFP expression in HEK293, MDCK and Hep-2 cell lines than unmodified
chitosan. Nanocomplexes of disulfide-crosslinked thiolated chitosan/DNA showed a sus‐
tained DNA release and continuous expression in cultured cells lasting up to 60 h post
transfection. Intranasal administration of crosslinked thiolated chitosan/DNA nanocomplexes
to mice yielded gene expression that lasted at least 14 days [34].
Nanoparticles containing the gene reporter pSEAP (recombinant Secreted Alkaline Phospha‐
tase) were generated, based on a thiolated chitosan conjugate, chitosan-TGA, crosslinked by
thiol oxidation with H2O2 to form disulfide crosslinks. Transfection of nanoparticles in Caco-2
cells led to increased protein expression compared to unmodified chitosan nanoparticles. Red
blood cells lysis tests provided evidence for no cytotoxicity of nanoparticles. On the basis of
their experimental results the authors stated that their crosslinked thiolated chitosan nano‐
particles showed the potential for being used as a non-viral vector system for gene therapy [33].
3.3. Amphiphilic derivatives
Amphiphilic derivatives resulted when hydrophobic structures were attached to the hydro‐
philic chitosan backbone. In aqueous milieu these derivatives would self-assemble into
nanoparticles to attain thermodynamic stability. Nanoparticles derived from the self-assembly
of amphiphilic derivatives were often intended for cancer therapy. Glycol chitosan (hydro‐
philic)-cholanic acid (hydrophobic) conjugates self-assembled to form nanoparticles, the in
vivo tissue distribution, time-dependent excretion and tumor accumulation of which were
monitored in tumor-bearing mice by Park et al. [37]. The particles exhibited prolonged blood
circulation time, decreased time-dependent excretion from the body, and increased tumor
accumulation with increasing polymer molecular weight. The enhanced tumor targeting by
nanoparticles made of high molecular weight glycol chitosan-cholanic acid was ascribed to a
better in vivo stability, related to an improvement in blood circulation time [37].
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Similar nanoparticles as the above,  formed from glycol chitosan-cholanic acid conjugate,
loaded with the anticancer drug camptothecin, exhibited significant antitumor effects and
high tumor targeting ability  towards MDA-MB231 human breast  cancer  xenografts  sub‐
cutaneously implanted in nude mice.  The significant  antitumor efficacy of  nanoparticles
was ascribed to both their prolonged blood circulation and high accumulation in tumors
through the EPR effect [39].
The  cellular  uptake  mechanism and  the  intracellular  fate  of  nanoparticles  formed from
glycol  chitosan  hydrophobically  modified  with  cholanic  acid  have  been  reported  [40].
These particles showed an enhanced distribution in the whole cells, compared to the pa‐
rent hydrophilic  glycol  chitosan polymer.  In vitro experiments with endocytic  inhibitors
suggested that  the  cellular  uptake of  these  nanoparticles  involved several  distinct  path‐
ways, e.g., clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropino‐
cytosis.  Such  a  property,  along  with  low  toxicity  and  biocompatibility  suggested  these
hydrophobically modified glycol chitosan nanoparticles as a versatile carrier for the intra‐
cellular delivery of therapeutic agents [40].
A further hydrophobically modified chitosan derivative from which self-assembled nanopar‐
ticles were obtained was oleoyl chitosan. The toxicity profile of the relevant nanoparticles,
evaluated in vitro via hemolysis test and MTT assay, was within acceptable limits. When
loaded with the antitumor drug doxorubicin, oleoyl chitosan nanoparticles exhibited inhibi‐
tory rates on different human cancer cells (A549, Bel-7402, HeLa, and SGC-7901) significantly
higher than the drug solution [43].
Folic acid was conjugated with O-carboxymethyl chitosan via the bifunctional 2,2’-(ethyl‐
enedioxy)-bis-(ethylamine)  to  obtain  an  amphiphilic  chitosan derivative  that  would self-
assemble  into  nanoparticles.  Folate-mediated  endocytosis  significantly  enhanced  the
cellular  targeting  of  nanoparticles,  thus  facilitating  apoptosis  of  cancer  cells  (HeLa,
B16F1). Doxorubicin could be loaded into the nanoparticles. It was observed that survival
in cancer cells treated with doxorubicin-loaded nanoparticles was lower than that of nor‐
mal cells in similar concentrations [75].
The ability of nanoparticles prepared by self-assembly of chitosan amphiphiles to promote
oral absorption of hydrophobic and hydrophilic drugs in rats was recently investigated by
Siew et al. [42], using quaternary ammonium palmitoyl glycol chitosan as the basic material.
The nanoparticles were found to enhance the oral absorption (Cmax) of griseofulvin and
cyclosporine A (hydrophobic) and, to a lesser extent, of ranitidine (hydrophilic). Hydrophobic
drug absorption was facilitated by the nanomedicine by: (a) increasing the drug dissolution
rate, (b) adhering to and penetrating the mucus layer, thus allowing intimate contact between
the drug and the GI epithelium absorptive cells, and (c) enhancing transcellular drug transport.
As for the absorption of the hydrophilic ranitidine, despite an 80% increase of Cmax there was
no appreciable opening of tight junctions by the nanoparticles. No uptake of this type of
nanoparticles by epithelial cells is reported [42].
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Polymer Drug Diameter(nm)
Zeta
potential
(mV)
Reference
quaternary ammonium palmitoyl glycol chitosan
griseofulvin
cyclosporin
A
ranitidine
100-500 not report‐ed [42]
glycol chitosan-5β-cholanic acid
none 300-400 10 [40]
O-carboxymethyl chitosan-2,2I,(ethylene dioxy)-bis-(ethylamine)-
folic acid
doxorubicin 150-200 10-20 [75]
glycol chitosan-5β-cholanic acid none 230-310 10-11 [37]
glycol chitosan-5β-cholanic acid camptothe‐cin 250-350
not report‐
ed [39]
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Polymer Drug Diameter(nm)
Zeta
potential
(mV)
Reference
oleoyl-chitosan
doxorubicin 250-350 not report‐ed [43]
Table 3. Main characteristics of nanoparticles based on anphiphilic chitosans
4. Concluding remarks
Three families of chitosan derivatives have been synthesized and used to prepare nanoparticles
for pharmaceutical application, namely, polycations obtained by introducing quaternary
ammonium groups on the polymer backbone; thiolated derivatives, and amphiphilic deriva‐
tives obtained by attaching hydrophobic structures to the chitosan or glycol chitosan backbone.
The nanoparticles prepared from the quaternary ammonium-chitosan derivatives, especially
via the PEC formation method, have shown improved stability and physical properties
(smaller size, higher zeta potential) compared to nanoparticles from unmodified chitosan. The
thiolated derivatives offered the opportunity to stabilize the nanoparticles by covalent
crosslinks formed from interchain thiol oxidation to disulfide, which made the particles stable
in the GI environment. The critical aggregation concentration of the amphiphilic hydrophob‐
ically modified chitosan derivatives is usually very low, which implies stability of the self
aggregates in dilute conditions, such as those encountered by the nanoparticles in the organ‐
ism. The nanoparticulate systems prepared from chitosan derivatives have generally shown
acceptable cytotoxicity. In accord with the known behavior of particles of a size smaller than
500 nm, they have shown endocytic uptake by cells. Smaller particles with higher zeta potential
have shown more aptitude to endocytosis. Ionotropically crosslinked TMC nanoparticles are
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a potential vehicle for transport of proteins across mucosal epithelia, as they have been found
to open the tight junctions between epithelial cells. Indeed, nanoparticles based on quaternized
chitosan are a promising vehicle for the oral administration of insulin, especially if the chitosan
derivative is conjugated with the specific ligand CSKSSDYQC peptide. Also interesting is the
nanosystem based on the quaternary ammonium-chitosan conjugate HTCC, which was orally
absorbed by the rat small intestine and subsequently accumulated in carcinoma tissue by the
EPR effect. These results are particularly intriguing as they open the prospect of a targeted oral
treatment of cancer by nanomedicine. Nanoparticles prepared from thiolated chitosan
derivatives have shown a particular mucoadhesivity implying a suitability for making
nanocarriers for transmucosal protein delivery. Also this type of nanoparticles have appeared
highly effective as gene delivery systems and have shown the potential for being used as a
non-viral vector system for gene therapy. Nanoparticles derived from the self-assembly of
amphiphilic chitosan derivatives were often intended for cancer therapy. Glycol chitosan
hydrophobically modified with cholanic acid yielded nanoparticles with comparatively high
in vivo stability, responsible for a prolonged blood circulation time, which led to high
accumulation in tumors through the EPR effect. This type of nanoparticles can be taken up by
cells through distinct pathways, which points to this system as a versatile carrier for the
intracellular delivery of therapeutic agents. Folic acid, conjugated with O-carboxymethyl
chitosan to obtain doxorubicin-loaded self-assembled nanoparticles, could mediate particle
endocytosis by cancer cells with consequent cell apoptosis. In conclusion the present survey
has endorsed the concept that chitosan derivatization can lead to new basic materials for
nanosystems with unique pharmaceutical performances.
Abbreviations
BSA Bovine serum albumin
CAC Critical aggregation concentration
CLSM Confocal laser scanning microscopy
CSK CSKSSDYQC peptide
DEMC N,N-diethyl N-methyl chitosan
DMEC N,N-dimethyl N-ethyl chitosan
EPR Enhanced permeability and retention effect
FD4 Fluorescein isothiocyanate dextran, molecular weight 4400 Da
FITC Fluorescein isothiocyanate
GFP Green fluorescent protein
GI Gastrointestinal
HA Hyaluronic acid
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HTCC N-(2-hydroxy-3-trimethylammonium) propyl chitosan chloride
LLC Lewis lung carcinoma
MCC Mono-N-carboxymethyl chitosan
NAC N-acetyl cysteine
NALT Nasal associated lymphoid tissue
OVA Ovalbumin
PEC Polyelectrolyte complex
pSEAP Recombinant secreted alkaline phosphatase
TBA Thiobutyl amidine
TEC N-triethyl chitosan
TGA Thioglycolic acid
TMC N-trimethyl chitosan
TPP Sodium tripolyphosphate
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